{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:02:30Z","timestamp":1790694150005,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd007478","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T00:00:00Z","timestamp":1615248000000}}],"reference-count":287,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007478.pub2","type":"journal-article","created":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T11:55:17Z","timestamp":1615290917000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Interventions for cutaneous disease in systemic lupus erythematosus"],"prefix":"10.1002","volume":"2021","author":[{"given":"Cora W","family":"Hannon","sequence":"additional","affiliation":[{"name":"Dermatologist, Masters of Public Health Program; Harvard School of Public Health; Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Collette","family":"McCourt","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Royal Victoria Hospital; Belfast UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermenio C","family":"Lima","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Clinical Unit for Research Trials and Outcomes in Skin (CURTIS); Massachusetts General Hospital; Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suephy","family":"Chen","sequence":"additional","affiliation":[{"name":"Emory University Hospital; Emory Healthcare; Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Bennett","sequence":"additional","affiliation":[{"name":"Office of Research and Innovation; Royal College of Surgeons in Ireland Col\u00e1iste R\u00edoga na M\u00e1inle\u00e1 in \u00c9irinn; Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,3,9]]},"reference":[{"issue":"5","key":"10.1002\/14651858.CD007478.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.reuma.2009.11.004","article-title":"Efficacy of rituximab versus cyclophosphamide in lupus patients with severe manifestations: a randomized and multicenter study","volume":"6","author":"Andrade-Ortega","year":"2010","journal-title":"Reumatologia Clinica"},{"issue":"10","key":"10.1002\/14651858.CD007478.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1002\/art.21358","article-title":"Double-blind randomized controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus","volume":"52","author":"Bezerra","year":"2005","journal-title":"Arthritis and Rheumatism"},{"issue":"8965","key":"10.1002\/14651858.CD007478.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/S0140-6736(95)90114-0","article-title":"Prevention of relapses in systemic lupus erythematosus","volume":"345","author":"Bootsma","year":"1995","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD007478.pub2-BIB0004|cit4","first-page":"1275","article-title":"Double blind, randomized controlled, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus","volume":"26","author":"Carneiro","year":"1999","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0005|cit5","article-title":"Efficacy and safety of epratuzumab in patients with moderate to severe systemic lupus erythematosus: results from two phase-3, placebo controlled trials","volume":"67","author":"Clowse","year":"2015","journal-title":"Arthritis and Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD007478.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s005990070017","article-title":"Cyclosporine-A plus steroids versus steroids alone in the 12-month treatment of systemic lupus erythematosus","volume":"30","author":"Dammacco","year":"2000","journal-title":"International Journal of Clinical Laboratory Research"},{"issue":"8","key":"10.1002\/14651858.CD007478.pub2-BIB0007|cit7","first-page":"1551","article-title":"The clinical effect of dietary supplementation with omega-3 fish oils and\/or copper in systemic lupus erythematosus","volume":"31","author":"Duffy","year":"2004","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0008|cit8","unstructured":"Safety and efficacy of topical R333 in patients with discoid lupus erythematosus (DLE) and systemic lupus erythematosus (SLE) lesions (SKINDLE) clinicaltrials.gov\/ct2\/show\/results\/NCT01597050"},{"issue":"12","key":"10.1002\/14651858.CD007478.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/art.24068","article-title":"Steroid sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo controlled trial","volume":"59","author":"Fortin","year":"2008","journal-title":"Arthritis and Rheumatism"},{"issue":"12","key":"10.1002\/14651858.CD007478.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B-lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis and Rheumatism"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD007478.pub2-BIB0011|cit11","first-page":"727","article-title":"Repository corticotropin injection (HP acthar gel) attenuates disease activity in patients with persistently active systemic lupus erythematosus requiring corticosteroids","volume":"67","author":"Furie","year":"2015","journal-title":"Clinical Experimental Rheumatology"},{"issue":"9","key":"10.1002\/14651858.CD007478.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1136\/annrheumdis-2013-205144","article-title":"A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematous, the PEARL-SC study","volume":"74","author":"Furie","year":"2015","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"10.1002\/14651858.CD007478.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis and Rheumatology"},{"issue":"4 Suppl 99","key":"10.1002\/14651858.CD007478.pub2-BIB0014|cit14","first-page":"S4","article-title":"Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, in moderate to severe systemic lupus erythematosus (SLE)","volume":"34","author":"Furie","year":"2016","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD007478.pub2-BIB0015|cit15","first-page":"Abstract 3223","article-title":"Anifrolumab, an anti-interferon alpha receptor monoclonal antibody, in moderate to severe systemic lupus erythematosus","volume":"67","author":"Furie","year":"2015","journal-title":"Arthritis and Rheumatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD007478.pub2-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1136\/annrheumdis-2016-eular.3919","article-title":"Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, in moderate to severe systemic lupus erythematosus (SLE)","volume":"75","author":"Furie","year":"2016","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4 Suppl 99","key":"10.1002\/14651858.CD007478.pub2-BIB0017|cit17","first-page":"S87","article-title":"Systemic lupus erythematosus (SLE) responder index [SRI(4)] response is associated with global benefit in patients with moderate to severe SLE","volume":"34","author":"Furie","year":"2016","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD007478.pub2-BIB0018|cit18","first-page":"2569","article-title":"The effect of anifrolumab on cutaneous manifestations and arthritis in moderate to severe systemic lupus erythematosus (SLE) using categorical SLEDAI-2K responses and continuous measures of activity as outcome measures","volume":"68","author":"Merrill","year":"2016","journal-title":"Arthritis and Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD007478.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"e000284","DOI":"10.1136\/lupus-2018-000284","article-title":"Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus","volume":"5","author":"Merrill","year":"2018","journal-title":"Lupus Science Medicine"},{"issue":"1","key":"10.1002\/14651858.CD007478.pub2-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"e000180","DOI":"10.1136\/lupus-2016-000180","article-title":"Efficacy and tolerability of repository corticotropin injection in patients with persistently active SLE: results of a phase 4, randomised, controlled pilot study","volume":"3","author":"Furie","year":"2016","journal-title":"Lupus Science and Medicine"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD007478.pub2-BIB0021|cit21","first-page":"1010","article-title":"Measures of disease activity in patients with persistently active systemic lupus erythematosus (SLE): results from a two-part 52 week pilot study of repository corticotropin injection (H.P. Acthar gel)","volume":"68","author":"Furie","year":"2016","journal-title":"Arthritis and Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD007478.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"e000240","DOI":"10.1136\/lupus-2017-000240","article-title":"Repository corticotropin injection in patients with persistently active SLE requiring corticosteroids: post hoc analysis of results from a two-part, 52-week pilot study","volume":"4","author":"Furie","year":"2017","journal-title":"Lupus Science and Medicine"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD007478.pub2-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1136\/annrheumdis-2017-eular.6259","article-title":"BIIB059, a monoclonal antibody targeting BDCA2, shows evidence of biological activity and early clinical proof of concept in subjects with active cutaneous lesions","volume":"76","author":"Furie","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD007478.pub2-BIB0024|cit24","first-page":"2576","article-title":"BIIB059, a monoclonal antibody targeting BDCA2, shows evidence of biological activity and early clinical proof of concept in subjects with active cutaneous SLE","volume":"68","author":"Furie","year":"2016","journal-title":"Arthritis and Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD007478.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1172\/JCI124466","article-title":"Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus","volume":"129","author":"Furie","year":"2019","journal-title":"Journal of Clinical Investigation"},{"issue":"4","key":"10.1002\/14651858.CD007478.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/rheumatology\/kep396","article-title":"The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE","volume":"49","author":"Griffiths","year":"2010","journal-title":"Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD007478.pub2-BIB0027|cit27","first-page":"462","article-title":"A pilot study of Zileuton, a novel selective 5-lipoxygenase inhibitor, in patients with systemic lupus erythematosus","volume":"22","author":"Hackshaw","year":"1995","journal-title":"Journal of Rheumatology"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD007478.pub2-BIB0028|cit28","article-title":"The first randomized control trial to evaluate the effectiveness of bortezomib for refractory systemic lupus erythematous","volume":"67","author":"Ishii","year":"2015","journal-title":"Arthritis and Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD007478.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1756-185X.2011.01665.x","article-title":"Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus","volume":"15","author":"Islam","year":"2012","journal-title":"International Journal of Rheumatic Diseases"},{"issue":"2","key":"10.1002\/14651858.CD007478.pub2-BIB0030|cit30","first-page":"221","article-title":"Nifedipine and Raynaud's phenomenon associated with connective tissue disease","volume":"4","author":"Kahan","year":"1985","journal-title":"International Angiology"},{"issue":"11","key":"10.1002\/14651858.CD007478.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1136\/annrheumdis-2015-208562","article-title":"Sifalimumab, an anti-interferon-alpha monoclonal antibody in moderate to severe systemic lupus erythematosus: a randomised double blind study","volume":"75","author":"Khamashta","year":"2016","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD007478.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jaad.2010.03.037","article-title":"Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle controlled trial","volume":"65","author":"Kuhn","year":"2011","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD007478.pub2-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1136\/annrheumdis-2019-eular.4837","article-title":"Quality of life in systemic lupus erythematosus with cutaneous damage on the face: cosmetic camouflage impact","volume":"78","author":"Lanna","year":"2019","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"6","key":"10.1002\/14651858.CD007478.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1191\/096120301678646137","article-title":"Hydroxychloroquine (HCQ) in lupus pregnancy: a double-blind and placebo-controlled study","volume":"10","author":"Levy","year":"2001","journal-title":"Lupus"},{"issue":"1","key":"10.1002\/14651858.CD007478.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/acr.22621","article-title":"Vitamin D supplementation in adolescents and young adults with juvenile systemic lupus erythematous for improvement in disease activity and fatigue scores: a randomized double-blind placebo-controlled trial","volume":"68","author":"Lima","year":"2016","journal-title":"Arthritis Care and Research"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0036|cit36","unstructured":"Lima GL A randomized double-blind placebo-controlled trial of vitamin D supplementation in juvenile-onset systemic lupus erythematosus www.teses.usp.br\/teses\/disponiveis\/5\/5165\/tde-14122015-120849\/pt-br.php"},{"issue":"4","key":"10.1002\/14651858.CD007478.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/096120339600500405","article-title":"Ultraviolet-A1 (340-400nm) irradiation therapy in systemic lupus erythematosus","volume":"5","author":"McGrath","year":"1996","journal-title":"Lupus"},{"issue":"3","key":"10.1002\/14651858.CD007478.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/096120339600500313","article-title":"Controlled trial with chloroquine diphosphate in systemic lupus erythematosus","volume":"5","author":"Meinao","year":"1996","journal-title":"Lupus"},{"issue":"1","key":"10.1002\/14651858.CD007478.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately to severely active systemic lupus erythematosus; the randomized, double blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis and Rheumatism"},{"issue":"4 Suppl 99","key":"10.1002\/14651858.CD007478.pub2-BIB0040|cit40","first-page":"S70","article-title":"De-convolution of whole blood transcriptomic data from a phase iib, randomized, double-blind, placebo-controlled trial of abatacept in systemic lupus erythematosus","volume":"34","author":"Bandyopadhyay","year":"2016","journal-title":"Clinical and experimental rheumatology"},{"issue":"10","key":"10.1002\/14651858.CD007478.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1002\/art.27601","article-title":"The efficacy and safety of abatacept in patients with non-life threatening manifestations of systemic lupus erythematosus results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis and Rheumatism"},{"issue":"11","key":"10.1002\/14651858.CD007478.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1136\/ard.2010.144485","article-title":"Safety profile and clinical activity of sifalimumab, a fully human anti-interferon- \u03b1 monoclonal antibody, in systemic lupus erythematosus: a phrase I, multi centre, double-blind randomised study","volume":"70","author":"Merrill","year":"2011","journal-title":"Annals of Rheumatic Diseases"},{"issue":"2","key":"10.1002\/14651858.CD007478.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/annrheumdis-2015-207654","article-title":"Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multi centre, randomised, double-blind, placebo-controlled study","volume":"75","author":"Merrill","year":"2016","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD007478.pub2-BIB0044|cit44","first-page":"972","article-title":"An anti-CD28 domain antibody, lulizumab, in systemic lupus erythematosus: results of a phase II study","volume":"70","author":"Merrill","year":"2018","journal-title":"Arthritis and Rheumatology"},{"issue":"9767","key":"10.1002\/14651858.CD007478.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomized placebo controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD007478.pub2-BIB0046|cit46","first-page":"1172","article-title":"Safety profile of belimumab, a BlyS-specific inhibitor, in patients with active systemic lupus erythematosus (SLE): Pooled data from phase 2 and 3 studies","volume":"62","author":"Wallace","year":"2010","journal-title":"Arthritis and Rheumatism"},{"issue":"9","key":"10.1002\/14651858.CD007478.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1136\/annrheumdis-2016-210882","article-title":"Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial","volume":"76","author":"Ordi-Ros","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"6","key":"10.1002\/14651858.CD007478.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1177\/0961203309102803","article-title":"An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus","volume":"18","author":"Pena-Rossi","year":"2009","journal-title":"Lupus"},{"issue":"9","key":"10.1002\/14651858.CD007478.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1002\/art.20427","article-title":"Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Results of a multicenter randomized double blind placebo controlled trial","volume":"50","author":"Petri","year":"2004","journal-title":"Arthritis and Rheumatism"},{"issue":"5","key":"10.1002\/14651858.CD007478.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1002\/art.27371","article-title":"High dose cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus erythematosus","volume":"62","author":"Petri","year":"2010","journal-title":"Arthritis and Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD007478.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/art.37824","article-title":"Sifalimumab, a human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus: a phase 1 randomized controlled, dose-escalation study","volume":"65","author":"Petri","year":"2013","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0052|cit52","unstructured":"Polderman MC Huizinga TW Breedveld FC Pavel S UVA-1 in the treatment of systemic lupus erythematosus (SLE) Nederlands Tijdschrift Voor Dermatologie en Venereologie 2000 10 150 1"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD007478.pub2-BIB0053|cit53","first-page":"S116","article-title":"Long wave UVA (UVA-1) in the treatment of systemic lupus erythematosus (SLE)","volume":"12","author":"Polderman","year":"1999","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"2","key":"10.1002\/14651858.CD007478.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/ard.60.2.112","article-title":"UVA-1 cold light treatment of SLE: a double blind, placebo controlled crossover trial","volume":"60","author":"Polderman","year":"2001","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"11","key":"10.1002\/14651858.CD007478.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1093\/rheumatology\/keh352","article-title":"Efficacy of UVA-1 cold light as an adjuvant therapy for systemic lupus erythematosus","volume":"43","author":"Polderman","year":"2004","journal-title":"Rheumatology (Oxford, England)"},{"issue":"4","key":"10.1002\/14651858.CD007478.pub2-BIB0056|cit56","first-page":"745","article-title":"Nicardipine for the treatment of Raynaud's phenomenon: a double blind crossover trial of a new calcium entry blocker","volume":"14","author":"Rupp","year":"1987","journal-title":"Journal of Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD007478.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/art.40049","article-title":"Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis and Rheumatology"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD007478.pub2-BIB0058|cit58","article-title":"A phase 1, randomized double-blind, placebo-controlled, multiple, intravenous, ascending dose study of sirukumab in patients with cutaneous or systemic lupus erythematosus","volume":"63","author":"Szepietowski","year":"2011","journal-title":"Arthritis and Rheumatism"},{"issue":"10","key":"10.1002\/14651858.CD007478.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1002\/art.38091","article-title":"Phrase I, randomized, double-blind, placebo-controlled, multiple intervenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus","volume":"65","author":"Szepietowski","year":"2013","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0060|cit60","unstructured":"Tillmanns S Kolligs C D'Cruz DP Doria A Hachulla E Voll RE SM101, a novel recombinant, soluble, human Fc\u028fIIB receptor, in the treatment of systemic lupus erythematosus: results of a double-blind, placebo-controlled trial acrabstracts.org\/abstract\/sm101-a-novel-recombinant-soluble-human-fc%CE%B3iib-receptor-in-the-treatment-of-systemic-lupus-erythematosus-results-of-a-double-blind-placebo-controlled-multicenter-study\/"},{"issue":"3","key":"10.1002\/14651858.CD007478.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJM199101173240303","article-title":"A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus","volume":"324","author":"Canadian Hydroxychloroquine Study Group","year":"1991","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD007478.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1191\/096120398678919778","article-title":"A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus","volume":"7","author":"Tsakonas","year":"1998","journal-title":"Lupus"},{"issue":"11","key":"10.1002\/14651858.CD007478.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1002\/art.22198","article-title":"The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial","volume":"54","author":"Tseng","year":"2006","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0064|cit64","unstructured":"Tzung TY Lin CB Liu YS Comparison of tacrolimus 0.1% ointment and clobetasol propionate 0.05% cream in the treatment of cutaneous lupus erythematosus of the face Journal of the European Academy of Dermatology and Venereology 2005 19 Suppl 2 347 8"},{"issue":"1","key":"10.1002\/14651858.CD007478.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2133.2006.07595.x","article-title":"Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double-blind, bilateral comparison study","volume":"156","author":"Tzung","year":"2007","journal-title":"British Journal of Dermatology"},{"issue":"12","key":"10.1002\/14651858.CD007478.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/art.1780381216","article-title":"Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo controlled, randomized clinical trial","volume":"38","author":"Van Vollenhoven","year":"1995","journal-title":"Arthritis and Rheumatism"},{"issue":"10155","key":"10.1002\/14651858.CD007478.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/S0140-6736(18)32167-6","article-title":"Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study","volume":"392","author":"Van Vollenhoven","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD007478.pub2-BIB0068|cit68","first-page":"102","article-title":"Sustained disease improvement and safety profile over 1745 patient-year experience (7 years) with belimumab in patients with systemic lupus erythematosus","volume":"22","author":"Merrill","year":"2013","journal-title":"Lupus"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007478.pub2-BIB0069|cit69","first-page":"74","article-title":"Safety and sustained disease activity improvement over the 1500 patient-year experience (6 years) with belimumab in SLE patients","volume":"15","author":"Merrill","year":"2012","journal-title":"International Journal of Rheumatic Diseases"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0070|cit70","unstructured":"Petri M Gallacher A Wallace DJ Thomas M Levy RA Van Vollenhoven RF Safety profile of belimumab in phase 2 and 3 clinical trials of patients with active SLE International Journal of Rheumatic Diseases 2012 15 Suppl 1 73 4"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD007478.pub2-BIB0071|cit71","first-page":"1172","article-title":"Safety profile of belimumab, a BlyS-specific inhibitor, in patients with active systemic lupus erythematosus (SLE): Pooled data from phase 2 and 3 studies","volume":"62","author":"Wallace","year":"2010","journal-title":"Arthritis and Rheumatism"},{"issue":"9","key":"10.1002\/14651858.CD007478.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/art.24699","article-title":"A phase II, randomized double-blind placebo controlled dose ranging study of belimumab in patients with active systemic lupus erythematosus","volume":"61","author":"Wallace","year":"2009","journal-title":"Arthritis and Rheumatism"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007478.pub2-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/1756-185x.12344","article-title":"Epratuzumab: improvements in disease activity and quality of life","volume":"17","author":"Hobbs","year":"2014","journal-title":"International Journal of Rheumatic Diseases"},{"issue":"7","key":"10.1002\/14651858.CD007478.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1093\/rheumatology\/ket129","article-title":"Efficacy and safety of epratuzumab in patients with moderate\/severe flaring systemic lupus erythematosus: results from two randomized,double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up","volume":"52","author":"Wallace","year":"2013","journal-title":"Rheumatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007478.pub2-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/1756-185x.12344","article-title":"Epratuzumab: improvements in disease activity over 2-years in SL0008C","volume":"17","author":"Gordon","year":"2014","journal-title":"International Journal of Rheumatic Disease"},{"issue":"4","key":"10.1002\/14651858.CD007478.pub2-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/acr.22694","article-title":"Long-term safety and efficacy of epratuzumab in the treatment of moderate-to- severe systemic lupus erythematosus: results from an open-label extension study","volume":"68","author":"Wallace","year":"2016","journal-title":"Arthritis Care and Research"},{"issue":"1","key":"10.1002\/14651858.CD007478.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1136\/annrheumdis-2012-202760","article-title":"Efficacy and safety of epratuzumab in patients with moderate\/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicenter study","volume":"73","author":"Wallace","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"S1","key":"10.1002\/14651858.CD007478.pub2-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/1756-185X.13361","article-title":"Baricitinib in systemic lupus erythematosus (SLE): results from a phase 2, randomized, double-blind, placebo-controlled study","volume":"21","author":"Tanaka","year":"2018","journal-title":"International Journal of Rheumatic Diseases"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD007478.pub2-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1136\/annrheumdis-2018-eular.1918","article-title":"Baricitinib in systemic lupus erythematosus (SLE): results from a phase 2, randomized, double-blind, placebo-controlled study","volume":"77","author":"Wallace","year":"2018","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"10143","key":"10.1002\/14651858.CD007478.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"The Lancet"},{"issue":"7","key":"10.1002\/14651858.CD007478.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1136\/ard.50.7.463","article-title":"Dietary fish oil and the severity of symptoms in patients with systemic lupus erythematosus","volume":"50","author":"Walton","year":"1991","journal-title":"Annals of Rheumatic Diseases"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD007478.pub2-BIB0082|cit82","first-page":"887","article-title":"A randomized, placebo-controlled, double-blind, ascending-dose, safety, and pharmacokinetics study of CC-220 in subjects with systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis and Rheumatism"},{"issue":"Suppl 99","key":"10.1002\/14651858.CD007478.pub2-BIB0083|cit83","first-page":"S77","article-title":"A phase 2, randomized, placebo-controlled, double blind, ascending dose study to evaluate efficacy, safety, and tolerability of CC 220 in subjects with systemic lupus erythematosus","volume":"34","author":"Furie","year":"2016","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD007478.pub2-BIB0084|cit84","first-page":"886","article-title":"CC-220 decreases B-cell subsets and plasmacytoid dendritic cells in systemic lupus erythematosus (SLE) patients and is associated with skin improvement: Pharmacodynamic results from a phase IIa proof of concept study","volume":"69","author":"Werth","year":"2017","journal-title":"Arthritis and Rheumatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD007478.pub2-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/annrheumdis-2017-eular.3546","article-title":"A randomized, placebo-controlled, double-blind, ascending-dose, safety study of CC-220 in subjects with systemic lupus erythematosus","volume":"76","author":"Werth","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"10.1002\/14651858.CD007478.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3109\/03009749009102117","article-title":"Effect of MaxEPA in Patients with SLE. A double-blind, crossover study","volume":"19","author":"Westberg","year":"1990","journal-title":"Scandavian Journal of Rheumatology"},{"issue":"8","key":"10.1002\/14651858.CD007478.pub2-BIB0087|cit87","first-page":"1457","article-title":"Comparison of hydroxychloroquine and placebo in the treatment of arthropathy of mild systemic lupus erythematosus","volume":"21","author":"Williams","year":"1994","journal-title":"Journal of Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD007478.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/ard.2007.077156","article-title":"A randomized interventional trail of omega-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus","volume":"67","author":"Wright","year":"2008","journal-title":"Annals of Rheumatic Diseases"},{"issue":"6","key":"10.1002\/14651858.CD007478.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/1756-185X.12179","article-title":"Open label randomized controlled trial assessing the efficacy of mycophenolate sodium against other conventional immunosuppressive agents in active systemic lupus erythematosus without renal involvement","volume":"16","author":"Yahya","year":"2013","journal-title":"International Journal of Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD007478.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/art.40018","article-title":"Effects of hydroxychloroquine in patients with cutaneous lupus erythematosus: A multicenter, double-blind, randomized, parallel-group trial","volume":"69","author":"Yokogawa","year":"2017","journal-title":"Arthritis and Rheumatology"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD007478.pub2-BIB0091|cit91","article-title":"A double-blind, randomized, parallel-group study of hydroxychloroquine on cutaneous lupus erythematosus in Japan","volume":"67","author":"Yokogawa","year":"2015","journal-title":"Arthritis and Rheumatology"},{"issue":"8","key":"10.1002\/14651858.CD007478.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3736\/jcim20100806","article-title":"Efficacy of ginsenosides combined with prednisone in patients with systemic lupus erythematosus: a prospective, randomized double blind placebo controlled trial","volume":"8","author":"You","year":"2010","journal-title":"Zhong Xi Yi Jie He Xue Bao [Journal of Chinese Integrative Medicine]"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0093|cit93","article-title":"Chinese herbal medicine (Zi Shen Qing) for mild-to-moderate systematic lupus erythematosus: a pilot prospective, single blinded randomized controlled study","volume":"327245","author":"Zhong","year":"2013","journal-title":"Evidence-Based Complementary and Alternative Medicine"},{"issue":"5","key":"10.1002\/14651858.CD007478.pub2-BIB0094|cit94","first-page":"797","article-title":"Fulvestrant (Faslodex), an estrogen selective receptor down-regulator, in therapy of women with systemic lupus erythematosus. clinical, serologic, bone density, and T cell activation marker studies: a double-blind placebo-controlled trial","volume":"35","author":"Abdou","year":"2008","journal-title":"Journal of Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD007478.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.reuma.2008.09.008","article-title":"Treating severe systemic lupus erythematosus with rituximab. An open study","volume":"5","author":"Abud-Mendoza","year":"2009","journal-title":"Reumatologia Clinica"},{"issue":"7","key":"10.1002\/14651858.CD007478.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1365-2230.2008.03138.x","article-title":"Pimecrolimus 1% cream versus betamethasone 17-valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double-blind randomized pilot study","volume":"34","author":"Barikbin","year":"2009","journal-title":"Clinical and Experimental Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD007478.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s00198-003-1553-6","article-title":"The effect of 1-year transdermal estrogen replacement therapy on bone mineral density and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial","volume":"15","author":"Bhattoa","year":"2004","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1365-2133.1963.tb13959.x","article-title":"Treatment of chronic discoid lupus erythematosus with fluocinolone acetonide ointment","volume":"75","author":"Bjornberg","year":"1963","journal-title":"British Journal of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD007478.pub2-BIB0099|cit99","first-page":"443","article-title":"Effects of radix astragali injection on apoptosis of lymphocytes and immune function in patients with systemic lupus erythematosus","volume":"26","author":"Cai","year":"2006","journal-title":"Zhongguo Zhong Xi Yi Jie He Za Zhi [Chinese Journal of Integrated Traditional and Western Medicine]"},{"issue":"11","key":"10.1002\/14651858.CD007478.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1002\/art.10615","article-title":"Dehydroepiandrosterone treatment of women with mild to moderate systemic lupus erythematosus, a multicenter randomized double-blind placebo-controlled trial","volume":"46","author":"Chang","year":"2002","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"19622","DOI":"10.1038\/srep19622","article-title":"Modulation of endothelial injury by traditional Chinese Medicine LC in systemic lupus erythematosus","volume":"6","author":"Chang","year":"2016","journal-title":"Scientific Reports"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0102|cit102","unstructured":"Clinical study about the SLEDAI-reducing and glucocorticoid-withdrawing effect on compound Qing Hao oral liquid on mild to moderate systemic lupus erythematosus www.chictr.org.cn\/showprojen.aspx?proj=7148"},{"issue":"5","key":"10.1002\/14651858.CD007478.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"R109","DOI":"10.1186\/ar2506","article-title":"Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus","volume":"10","author":"Furie","year":"2008","journal-title":"Arthritis Research and Therapy"},{"issue":"S10","key":"10.1002\/14651858.CD007478.pub2-BIB0104|cit104","first-page":"S962","article-title":"Efficacy and safety of abatacept over 12 months in patients with lupus nephritis: Results from a multicenter, randomized, double-blind, placebo-controlled phase II\/III study","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis and Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD007478.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3899\/jrheum.121368","article-title":"Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus","volume":"41","author":"Ginzler","year":"2014","journal-title":"Journal of Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD007478.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/rheumatology\/kem342","article-title":"Testosterone patches in the management of patients with mild\/moderate systemic lupus erythematosus","volume":"47","author":"Gordon","year":"2008","journal-title":"Rheumatology (Oxford, England)"},{"issue":"5","key":"10.1002\/14651858.CD007478.pub2-BIB0107|cit107","first-page":"261","article-title":"A randomized double-blind study of ointments containing diflucortolone valerate and hydrocortisone acetate","volume":"51","author":"Handa","year":"1985","journal-title":"Indian Journal of Dermatology, Venereology and Leprology"},{"issue":"S1","key":"10.1002\/14651858.CD007478.pub2-BIB0108|cit108","first-page":"3725","article-title":"Low-dose interleukin-2 selectively modifies CD4+ T cell subsets in SLE","volume":"46","author":"He","year":"2016","journal-title":"European Journal of Immunology"},{"issue":"12","key":"10.1002\/14651858.CD007478.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1136\/annrheumdis-2012-201536","article-title":"A multi-centre, blinded, randomised, placebo-controlled, laboratory-based study of mqx-503, a novel topical gel formulation of nitroglycerine, in patients with Raynaud's phenomenon","volume":"72","author":"Hummers","year":"2013","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"6","key":"10.1002\/14651858.CD007478.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1111\/j.1365-2133.2009.09330.x","article-title":"A randomized controlled trial of R-salbutamol for topical treatment of discoid lupus erythematosus","volume":"161","author":"Jemec","year":"2009","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD007478.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1177\/0961203316640910","article-title":"Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus","volume":"25","author":"Kahl","year":"2016","journal-title":"Lupus"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000254544","article-title":"The value of hydroxychloroquine (Plaquenil) for the treatment of chronic discoid lupus erythematosus; a double blind trial","volume":"130","author":"Kraak","year":"1965","journal-title":"Dermatologica"},{"issue":"1","key":"10.1002\/14651858.CD007478.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2009.12.053","article-title":"Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: a randomized, vehicle-controlled, double-blind study","volume":"64","author":"Kuhn","year":"2011","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"7","key":"10.1002\/14651858.CD007478.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.kjms.2011.03.001","article-title":"Preliminary study of a traditional Chinese medicine formula in systemic lupus erythematosus patients to taper steroid dose and prevent disease flare-up","volume":"27","author":"Liao","year":"2011","journal-title":"Kaohsiung Journal of Medical Sciences"},{"issue":"12","key":"10.1002\/14651858.CD007478.pub2-BIB0115|cit115","first-page":"1669","article-title":"The effectiveness of Zi Shen Qing formula on regulation of CD4, CD25 with mild to moderate active systemic lupus erythematosus","volume":"34","author":"Liu","year":"2007","journal-title":"Liao Ning Journal of Traditional Chinese Medicine"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD007478.pub2-BIB0116|cit116","first-page":"738","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the BCL-2 Inhibitor venetoclax (ABT-199) in a phase 1 single and multiple ascending dose study in female patients with systemic lupus erythematosus","volume":"67","author":"Lu","year":"2015","journal-title":"Arthritis and Rheumatism"},{"issue":"9","key":"10.1002\/14651858.CD007478.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/acr.22837","article-title":"Hydroxychloroquine serum concentrations and flares of systemic lupus erythematosus: a longitudinal cohort analysis","volume":"68","author":"Mok","year":"2016","journal-title":"Arthritis Care and Research"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0118|cit118","unstructured":"Treatment of cutaneous lupus erythematosus (CLE) with 595 NM flash lamp pulsed dye laser clinicaltrials.gov\/ct2\/show\/NCT00523588"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0119|cit119","unstructured":"Treatment of systemic lupus erythematosus (SLE) with N-acetylcysteine (NAC) clinicaltrials.gov\/ct2\/show\/NCT00775476"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0120|cit120","unstructured":"A study to evaluate the efficacy and safety of CEP-33457 in patients with systemic lupus erythematosus clinicaltrials.gov\/ct2\/show\/NCT01135459"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0121|cit121","unstructured":"A multiple dose study of PD-0360324 in patients with active cutaneous lupus erythematosus clinicaltrials.gov\/ct2\/show\/NCT01470313"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0122|cit122","unstructured":"Vitamin D status, disease specific and quality of life outcomes in patients with cutaneous lupus clinicaltrials.gov\/ct2\/show\/NCT01498406"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0123|cit123","unstructured":"Photoprovocation testing in subjects with cutaneous lupus clinicaltrials.gov\/ct2\/show\/NCT01516788"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0124|cit124","unstructured":"An investigation of safety and tolerability of NNC0114-0006 in subjects with systemic lupus erythematosus (SLE) clinicaltrials.gov\/ct2\/show\/NCT01689025"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0125|cit125","unstructured":"Vitamin D3 treatment in pediatric systemic lupus erythematosus clinicaltrials.gov\/ct2\/show\/NCT01709474"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0126|cit126","unstructured":"CHABLIS-SC2: a study of the efficacy and safety of subcutaneous blisibimod in subjects with systemic lupus erythematosus with or without nephritis clinicaltrials.gov\/ct2\/show\/NCT02074020"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0127|cit127","unstructured":"Safety and efficacy of BMS-931699 versus placebo to treat systemic lupus erythematosus clinicaltrials.gov\/ct2\/show\/NCT02265744"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0128|cit128","unstructured":"CHABLIS7.5: a study of the efficacy and safety of subcutaneous blisibimod in subjects with systemic lupus erythematosus with or without nephritis clinicaltrials.gov\/ct2\/show\/NCT02514967"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0129|cit129","unstructured":"TAB08 in patients with systemic lupus erythematosus (SLE), not adequately controlled with current treatment clinicaltrials.gov\/ct2\/show\/NCT02711813"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0130|cit130","unstructured":"A phase II study of M2951 in systemic lupus erythematosus (SLE) clinicaltrials.gov\/ct2\/show\/NCT02975336"},{"issue":"7","key":"10.1002\/14651858.CD007478.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1080\/08916930500285550","article-title":"Effects of dehydroepiandrosterone supplement of health related quality of life in glucocorticosteroid treated female patients with systemic lupus erythematosus","volume":"38","author":"Nordmark","year":"2005","journal-title":"Autoimmunity"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0132|cit132","first-page":"S667 Abstract #","article-title":"Efficacy of tacrolimus combination therapy during maintenance phase of systemic lupus erythematosus","volume":"65","author":"Ohtsuka","year":"2013","journal-title":"Arthritis and Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD007478.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jaad.2013.11.007","article-title":"Lenalidomide in treatment-refractory cutaneous lupus erythematosus: efficacy and safety in a 52-week trial","volume":"70","author":"Okon","year":"2014","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"9","key":"10.1002\/14651858.CD007478.pub2-BIB0134|cit134","first-page":"1418","article-title":"Seluang fish (Rasbora Spp.) oil decreases inflammatory cytokines via increasing vitamin D level in systemic lupus erythematosus","volume":"7","author":"Partan","year":"2019","journal-title":"Macedonia Journal of Medical Science"},{"issue":"7","key":"10.1002\/14651858.CD007478.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/art.10364","article-title":"Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus","volume":"46","author":"Petri","year":"2002","journal-title":"Arthritis and Rheumatism"},{"issue":"7","key":"10.1002\/14651858.CD007478.pub2-BIB0136|cit136","first-page":"933","article-title":"A comparative study in efficacy and safety of 0.1% tacrolimus and 0.05% clobetasol propionate ointment in discoid lupus erythematosus by modified cutaneous lupus erythematosus disease area and severity index","volume":"95","author":"Pothinamthong","year":"2012","journal-title":"Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]"},{"issue":"6","key":"10.1002\/14651858.CD007478.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/bjd.16337","article-title":"Computerized planimetry to assess clinical responsiveness in a phase II randomized trial of topical R333 for discoid lupus erythematosus","volume":"178","author":"Presto","year":"2018","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD007478.pub2-BIB0138|cit138","first-page":"281","article-title":"Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy","volume":"25","author":"Roenigk","year":"1980","journal-title":"Cutis; Cutaneous Medicine for the Practitioner"},{"issue":"1","key":"10.1002\/14651858.CD007478.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.kint.2018.08.025","article-title":"A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney International"},{"issue":"5","key":"10.1002\/14651858.CD007478.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2133.1992.tb14851.x","article-title":"Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine","volume":"127","author":"Ruzicka","year":"1992","journal-title":"British Journal of Dermatology"},{"issue":"7","key":"10.1002\/14651858.CD007478.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/ptr.5827","article-title":"A randomized, double blind, placebo controlled, clinical trial examining the effects of green tea extract on SLE activity and quality of life","volume":"31","author":"Shamekhi","year":"2017","journal-title":"Phytotherapy Research : PTR"},{"issue":"6","key":"10.1002\/14651858.CD007478.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1034\/j.1600-0781.2000.160604.x","article-title":"Evaluation of the capacity of sunscreens\u00a0to photoprotect lupus erythematosus patients by employing the photoprovocation test","volume":"16","author":"Stege","year":"2000","journal-title":"Photodermatology, Photoimmunology and Photomedicine"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0143|cit143","first-page":"S188","article-title":"Topical pimecrolimus for cutaneous lupus erythematosus-results of a double blind placebo controlled trial","volume":"5","author":"Sticherling","year":"2007","journal-title":"Journal der Deutschen Dermatologischen Gesellschaft"},{"issue":"1","key":"10.1002\/14651858.CD007478.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3109\/14397595.2015.1079292","article-title":"Safety, pharmacokinetics, and pharmacodynamics of epratuzumab in Japanese patients with moderate-to-severe systemic lupus erythematosus: Results from a phase 1\/2 randomized study","volume":"26","author":"Tsuru","year":"2016","journal-title":"Modern Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD007478.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.maturitas.2008.12.021","article-title":"Tibolone in postmenopausal women with systemic lupus erythematosus: a pilot study","volume":"62","author":"Vieira","year":"2009","journal-title":"Maturitas"},{"issue":"7","key":"10.1002\/14651858.CD007478.pub2-BIB0146|cit146","first-page":"407","article-title":"A tablet of Tripterygium wilfordii in treating lupus erythematosus","volume":"9","author":"Wang","year":"1989","journal-title":"Zhong Xi Yi Jie He Za Zhi [Chinese Journal of Modern Developments in Traditional Medicine]"},{"issue":"S10","key":"10.1002\/14651858.CD007478.pub2-BIB0147|cit147","first-page":"S682","article-title":"A phase I single-dose crossover study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical efficacy of AMG 811 (anti-IFN-gamma) in subjects with discoid lupus erythematosus","volume":"65","author":"Werth","year":"2013","journal-title":"Arthritis and Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD007478.pub2-BIB0148|cit148","first-page":"33","article-title":"Effects of Ziyin Jiedu Quyu decoction on glucocorticoid dosage in systemic lupus erythematosus: a double blind randomized controlled trial","volume":"46","author":"Xu","year":"2012","journal-title":"Shang Hai Journal of Traditional Chinese Medicine"},{"issue":"3","key":"10.1002\/14651858.CD007478.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s10067-018-4348-z","article-title":"Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial","volume":"38","author":"Zhang","year":"2019","journal-title":"Clinical Rheumatology"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0150|cit150","unstructured":"Askanase AD Zhao E Zhu J Connolly-Strong E Furie RA A multicenter, double-blind, randomised, placebo-controlled, 24-week clinical trial evaluating the effect of repository corticotropin injection (RCI) in reducing disease activity for patients with persistently active SLE despite moderate-dose corticosteroid use Lupus (first accessed on September 8, 2020)"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0151|cit151","first-page":"1","article-title":"Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial","volume":"0","author":"Brunner","year":"2020","journal-title":"Annals of Rheumatological Disease"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0152|cit152","unstructured":"Paediatric lupus trial of belimumab plus background standard therapy (PLUTO) clinicaltrials.gov\/ct2\/show\/NCT01649765"},{"issue":"7","key":"10.1002\/14651858.CD007478.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/art.40828","article-title":"Safety and tolerability of Omalizumab: a randomized clinical trial of humanized anti-IgE monoclonal antibody in systemic lupus erythematosus","volume":"71","author":"Hasni","year":"2019","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0154|cit154","unstructured":"Omalizumab for lupus clinicaltrials.gov\/ct2\/show\/NCT01716312"},{"issue":"1","key":"10.1002\/14651858.CD007478.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","article-title":"Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial","volume":"79","author":"He","year":"2020","journal-title":"Annals Rheumological Disease"},{"issue":"3","key":"10.1002\/14651858.CD007478.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/annrheumdis-2019-216379","article-title":"IFN-\u03b1 kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study","volume":"79","author":"Houssiau","year":"2020","journal-title":"Annals of Rheumological Disease"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0157|cit157","unstructured":"A phase II study to evaluate safety and efficacy of ALX-0061 in subjects with systemic lupus erythematosus clinicaltrials.gov\/ct2\/show\/NCT02437890"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0158|cit158","unstructured":"Efficacy and safety of anifrolumab compared to placebo in adult subjects with active systemic lupus erythematosus clinicaltrials.gov\/ct2\/show\/NCT02446899"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0159|cit159","unstructured":"Efficacy and safety of two doses of anifrolumab compared to placebo in adult subjects with active systemic lupus erythematosus clinicaltrials.gov\/ct2\/show\/NCT02446912"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0160|cit160","unstructured":"Proof of concept study with BT063 in subjects with systemic lupus erythematosus (BT063 in SLE) clinicaltrials.gov\/ct2\/show\/NCT02554019"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0161|cit161","unstructured":"Study to evaluate BIIB059 in cutaneous lupus erythematosus (CLE) with or without systemic lupus erythematosus (SLE) (LILAC) clinicaltrials.gov\/ct2\/show\/NCT02847598"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0162|cit162","unstructured":"Efficacy and safety of twice-daily application of delgocitinib cream 20 mg\/g for 6 weeks in subjects with active discoid lupus erythematosus clinicaltrials.gov\/ct2\/show\/NCT03958955"},{"issue":"2","key":"10.1002\/14651858.CD007478.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/14397595.2019.1630897","article-title":"Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial","volume":"30","author":"Tanaka","year":"2020","journal-title":"Modern Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD007478.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/art.40052","article-title":"Brief report: pharmacodynamics, safety, and clinical efficacy of AMG 811, a human anti-interferon-gamma antibody, in patients with discoid lupus erythematosus","volume":"69","author":"Werth","year":"2017","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0165|cit165","unstructured":"Belimumab after B-cell depletion as new treatment for systemic lupus erythematosus www.isrctn.com\/search?q=ISRCTN47873003"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0166|cit166","unstructured":"Dipyridamole assessment for flare reduction in systemic lupus erythematosus (SLE) clinicaltrials.gov\/ct2\/show\/NCT01781611"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0167|cit167","unstructured":"Clarification of abatacept effects in SLE with integrated biologic and clinical approaches (ABC) clinicaltrials.gov\/ct2\/show\/NCT02270957"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0168|cit168","unstructured":"A phase 2a of RSLV-132 in subjects with systemic lupus erythematosus (SLE) clinicaltrials.gov\/ct2\/show\/NCT02660944"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0169|cit169","unstructured":"Using the cholinergic anti-inflammatory pathway to treat systemic lupus musculoskeletal pain clinicaltrials.gov\/ct2\/show\/NCT02822989"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0170|cit170","unstructured":"Phase 2, multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of an oral treatment regimen of CC-220 versus placebo in adult subjects with active systemic lupus erythematosus clinicaltrials.gov\/ct2\/show\/NCT03161483"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0171|cit171","unstructured":"An investigational study to evaluate BMS-986165 in patients with systemic lupus erythematosus clinicaltrials.gov\/ct2\/show\/NCT03252587"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0172|cit172","unstructured":"Safety and efficacy of AMG 592 in subjects with active systemic lupus erythematosus clinicaltrials.gov\/ct2\/show\/NCT03451422"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0173|cit173","unstructured":"A multicenter, randomized, double-blind, placebo-controlled, parallel-group study of ustekinumab in subjects with active systemic lupus erythematosus clinicaltrials.gov\/ct2\/show\/NCT03517722"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0174|cit174","unstructured":"A randomized, double-blind, placebo-controlled, parallel-group, phase 3 study of baricitinib in patients with systemic lupus erythematosus (Brave 1 trial) clinicaltrials.gov\/ct2\/show\/NCT031616912"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0175|cit175","unstructured":"A randomized, double-blind, placebo-controlled, parallel-group, phase 3 study of baricitinib in patients with systemic lupus erythematosus (BRAVE II trial) clinicaltrials.gov\/ct2\/show\/NCT03616964"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0176|cit176","unstructured":"A phase 2b multicenter dose ranging study to evaluate efficacy and safety of PF-06700841 in systemic lupus erythematosus www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2018-004175-12-BG"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0177|cit177","unstructured":"A multicenter, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of ABBV-105 and upadacitinib given alone or in combination (ABBV-599 Combination) in subjects with moderately to severely active systemic lupus erythematosus www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2019-000638-20-ES"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0178|cit178","unstructured":"A study to evaluate the efficacy and safety of AMG 570 in subjects with active systemic lupus erythematosus (SLE) with inadequate response to standard of care (SOC) therapy clinicaltrials.gov\/ct2\/show\/NCT04058028"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0179|cit179","unstructured":"A multicenter, randomized, double-blind, placebo-controlled, parallel-group study of ustekinumab in Chinese subjects with active systemic lupus erythematosus clinicaltrials.gov\/ct2\/show\/NCT04060888"},{"issue":"3","key":"10.1002\/14651858.CD007478.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"e025687","DOI":"10.1136\/bmjopen-2018-025687","article-title":"Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol","volume":"9","author":"Teng","year":"2019","journal-title":"BMJ Open"},{"issue":"11","key":"10.1002\/14651858.CD007478.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1191\/0961203304lu2020oa","article-title":"Dermatology position paper on the revision of the 1982 ACR Criteria for systemic lupus erythematosus","volume":"13","author":"Albrecht","year":"2004","journal-title":"Lupus"},{"issue":"2","key":"10.1002\/14651858.CD007478.pub2-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1529-8019.2007.00117.x","article-title":"Development of the CLASI as an outcome instrument for cutaneous lupus erythematosus","volume":"20","author":"Albrecht","year":"2007","journal-title":"Dermatology Therapy"},{"issue":"11","key":"10.1002\/14651858.CD007478.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1002\/art.20628","article-title":"The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity","volume":"50","author":"American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Reponse Criteria","year":"2004","journal-title":"Arthritis and Rheumatism"},{"issue":"7454","key":"10.1002\/14651858.CD007478.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations. The Grade Working Group","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD007478.pub2-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/0738-081X(92)90090-L","article-title":"Dermatologic criteria for classifying the major forms of cutaneous lupus erythematosus: methods for systematic discriminant analysis and question on the interpretation of findings","volume":"10","author":"Beutner","year":"1992","journal-title":"Clinics in Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD007478.pub2-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/art.1780350606","article-title":"Derivation of the SLEDAI: a disease activity index for lupus patients. The Committee on Prognosis Studies in SLE","volume":"35","author":"Bombardier","year":"1992","journal-title":"Arthritis and Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD007478.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/archderm.144.2.173","article-title":"The cutaneous lupus erythematosus disease area and severity index: a responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus","volume":"144","author":"Bonilla-Martinez","year":"2008","journal-title":"Archives of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD007478.pub2-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1053\/berh.2001.0224","article-title":"Management of skin disease in patients with lupus erythematosus","volume":"16","author":"Callen","year":"2002","journal-title":"Best Practice & Research: Clinical Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD007478.pub2-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/j.1365-2133.2004.06196.x","article-title":"Update on the management of cutaneous lupus erythematosus","volume":"151","author":"Callen","year":"2004","journal-title":"British Journal of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD007478.pub2-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.berh.2005.05.003","article-title":"Management of \"refractory\" skin disease patients with lupus erythematosus","volume":"19","author":"Callen","year":"2005","journal-title":"Best Practice & Research: Clinical Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD007478.pub2-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1440-0960.2006.00217.x","article-title":"Cutaneous lupus erythematosus: a personal approach to management","volume":"47","author":"Callen","year":"2006","journal-title":"Australasian Journal of Dermatology"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0192|cit192","unstructured":"Callen JP Lupus erythematosus, subacute cutaneous eMedicine, www.emedicine.com\/derm\/topic248.htm 2007"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0193|cit193","unstructured":"Cates C EMB Website www.nntonline.net 2003"},{"issue":"2","key":"10.1002\/14651858.CD007478.pub2-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00005792-199303000-00005","article-title":"Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1000 patients. The European Working Party on Systemic Lupus Erythematosus","volume":"72","author":"Cervera","year":"1993","journal-title":"Medicine"},{"issue":"10","key":"10.1002\/14651858.CD007478.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1080\/1744666X.2016.1188006","article-title":"Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects","volume":"12","author":"Chang","year":"2016","journal-title":"Expert Review of Clinical Immunology"},{"issue":"1","key":"10.1002\/14651858.CD007478.pub2-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/bjd.15312","article-title":"Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: A systematic review and meta-analysis","volume":"177","author":"Chasset","year":"2017","journal-title":"British Journal of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD007478.pub2-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jaad.2017.09.059","article-title":"Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: A systematic review and meta-analysis","volume":"78","author":"Chasset","year":"2017","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/B978-0-323-47927-1.00033-5","volume-title":"Dubois' Lupus Erythematosus and Related Syndromes","author":"Chong","year":"2019"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0199|cit199","first-page":"643","article-title":"Preliminary criteria for the classification of systemic lupus erythematosus","volume":"21","author":"Cohen","year":"1971","journal-title":"Bulletin of Rheumatologic Disease"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0200|cit200","unstructured":"Cochrane Skin - Core Outcome Set Initiative (CS-COUSIN) cs-cousin.org\/"},{"issue":"12","key":"10.1002\/14651858.CD007478.pub2-BIB0201|cit201","first-page":"889","article-title":"Drug induced lupus erythematosus with emphasis on skin manifestations and the role of anti-TNF agents","volume":"10","author":"Dalle Vedove","year":"2012","journal-title":"Journal der Deutschen Dermatologischen Gesellschaft"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0202|cit202","unstructured":"Dharmananda S Treatment of systemic lupus erythematosus (SLE) with Chinese Herbs www.itmonline.org\/arts\/lupus.htm"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jaut.2016.06.010","article-title":"Immunomodulators in SLE: clinical evidence and immunologic actions","volume":"74","author":"Durcan","year":"2016","journal-title":"Journal of Autoimmunity"},{"issue":"3","key":"10.1002\/14651858.CD007478.pub2-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/archdermatol.2009.21","article-title":"Incidence of a cutaneous lupus erythematosus, 1965-2005: a population-based study","volume":"145","author":"Durosaro","year":"2009","journal-title":"Archives of Dermatology"},{"issue":"7","key":"10.1002\/14651858.CD007478.pub2-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2165\/00128071-200304070-00002","article-title":"Cutaneous lupus erythematosus: diagnosis and management","volume":"4","author":"Fabbri","year":"2003","journal-title":"American Journal of Clinical Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD007478.pub2-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.semarthrit.2019.07.010","article-title":"Management of cutaneous manifestations of lupus erythematosus: A systematic review","volume":"50","author":"Fairley","year":"2020","journal-title":"Seminars in Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0207|cit207","first-page":"1091","volume-title":"Rheumatology","author":"Feldman","year":"2019"},{"issue":"8","key":"10.1002\/14651858.CD007478.pub2-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.autrev.2018.02.011","article-title":"The 2018 pipeline of targeted therapies under clinical development for Systemic Lupus Erythematosus: a systematic review of trials","volume":"17","author":"Felten","year":"2018","journal-title":"Autoimmunity review"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0209|cit209","first-page":"455","volume-title":"Evidence Based Dermatology","author":"Fett","year":"2011"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"1143\u201351","DOI":"10.1002\/art.24698","article-title":"Novel evidence-based systemic lupus erythematosus responder index","volume":"61","author":"Furie","year":"2009","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0211|cit211","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3389\/fimmu.2019.00275","article-title":"Effect of in vivo hydroxychloroquine and ex-vivo anti-BDCA2 mAb treatment on pDC IFN-alpha production from patients affected with cutaneous lupus erythematosus","volume":"10","author":"Gardet","year":"2019","journal-title":"Frontiers in Immunology"},{"issue":"4","key":"10.1002\/14651858.CD007478.pub2-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0190-9622(81)80261-7","article-title":"Distinctive cutaneous subsets in the spectrum of lupus erythematosus","volume":"4","author":"Gilliam","year":"1981","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD007478.pub2-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0307-742X(21)00208-3","article-title":"Skin manifestations of SLE","volume":"8","author":"Gilliam","year":"1982","journal-title":"Clinics in Rheumatic Diseases"},{"issue":"11","key":"10.1002\/14651858.CD007478.pub2-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s11926-013-0378-3","article-title":"Updated review of complementary and alternative medicine treatments for systemic lupus erythematosus","volume":"15","author":"Greco","year":"2013","journal-title":"Current Rheumatology Report"},{"issue":"9","key":"10.1002\/14651858.CD007478.pub2-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1365-4362.1993.tb04018.x","article-title":"Classification of lupus erythematosus","volume":"32","author":"Halmi","year":"1993","journal-title":"International Journal of Dermatology"},{"issue":"13","key":"10.1002\/14651858.CD007478.pub2-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1001\/jama.1983.03330370053031","article-title":"If nothing goes wrong, is everything alright?","volume":"249","author":"Hanley","year":"1983","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0217|cit217","volume-title":"A systematic review of interventions for cutaneous lupus erythematosus [Masters thesis]","author":"Hannon","year":"2008"},{"issue":"7","key":"10.1002\/14651858.CD007478.pub2-BIB0218|cit218","first-page":"447","article-title":"The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus","volume":"86","author":"Hay","year":"1993","journal-title":"QJM : Monthly Journal of the Association of Physicians"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0219|cit219","first-page":"257","article-title":"Evidence-based evaluation of immunomodulatory therapy for the cutaneous manifestations of lupus","volume":"20","author":"Heath","year":"2004","journal-title":"Advances in Dermatology"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0220|cit220","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/1502107","article-title":"Effects of integrated traditional Chinese and Western medicine for the treatment of lupus nephritis: A meta-analysis of randomized trials","volume":"0","author":"Heng","year":"2016","journal-title":"Evidence Based Complementary and Alternative Medicine"},{"issue":"9","key":"10.1002\/14651858.CD007478.pub2-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1002\/art.20426","article-title":"Use of sunscreens to protect against ultraviolet-induced lupus erythematosus","volume":"50","author":"Herzinger","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0222|cit222","unstructured":"Higgins JP Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"9","key":"10.1002\/14651858.CD007478.pub2-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis and Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD007478.pub2-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"817\u201328","DOI":"10.1002\/acr.22502","article-title":"Epidemiology of Systemic Lupus Erythematosus and Cutaneous Lupus in a predominantly white population in the United States","volume":"67","author":"Jarukitsopa","year":"2015","journal-title":"Arthritis Care and Research"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0225|cit225","first-page":"605","volume-title":"Evidence-based dermatology","author":"Jessop","year":"2003"},{"issue":"4","key":"10.1002\/14651858.CD007478.pub2-BIB0226|cit226","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002954.pub2","article-title":"Drugs for discoid lupus erythematosus","author":"Jessop","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD007478.pub2-BIB0227|cit227","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002954.pub3","article-title":"Drugs for discoid lupus erythematosus","author":"Jessop","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD007478.pub2-BIB0228|cit228","first-page":"505","article-title":"The effect of age on clinical and serological manifestations in unselected patients with systemic lupus erythematosus","volume":"15","author":"Jonsson","year":"1988","journal-title":"Journal of Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD007478.pub2-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1529-8019.2007.00131.x","article-title":"New concepts in antimalarial use and mode of action in dermatology","volume":"20","author":"Kalia","year":"2007","journal-title":"Dermatologic Therapy"},{"issue":"6","key":"10.1002\/14651858.CD007478.pub2-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1185\/03007990902929104","article-title":"New directions in the treatment of systemic lupus erythematosus","volume":"25","author":"Kalunian","year":"2009","journal-title":"Current Medical Research and Opinions"},{"issue":"5","key":"10.1002\/14651858.CD007478.pub2-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jaad.2010.02.008","article-title":"Quality of life in cutaneous lupus erythematosus","volume":"64","author":"Klein","year":"2011","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD007478.pub2-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/art.23319","article-title":"The Cutaneous Lupus Erythematosus Disease and Severity Index: Expansion for Rheumatology and Dermatology","volume":"59","author":"Krathen","year":"2008","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0233|cit233","volume-title":"Hautklinik","author":"Kuhn","year":"2003"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0234|cit234","doi-asserted-by":"crossref","DOI":"10.1007\/b137847","volume-title":"Cutaneous Lupus Erythematosus","author":"Kuhn","year":"2005"},{"issue":"6","key":"10.1002\/14651858.CD007478.pub2-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1016\/j.jaad.2010.06.018","article-title":"Cutaneous lupus erythematosus: update of therapeutic options. Part I","volume":"65","author":"Kuhn","year":"2011","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD007478.pub2-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1016\/j.jaad.2010.06.017","article-title":"Cutaneous lupus erythematosus: update of therapeutic options. Part II","volume":"65","author":"Kuhn","year":"2011","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD007478.pub2-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/jdv.14053","article-title":"S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European dermatology forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)","volume":"31","author":"Kuhn","year":"2017","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0238|cit238","first-page":"601","volume-title":"Dermatology","author":"Lee","year":"2003"},{"issue":"5","key":"10.1002\/14651858.CD007478.pub2-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1365-2230.2008.03006.x","article-title":"Systematic administration of chloroquine in discoid lupus erythematosus reduces skin lesions via inhibition of angiogenesis","volume":"34","author":"Lesiak","year":"2009","journal-title":"Clinical and Experimental Dermatology"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0240|cit240","first-page":"173","article-title":"Emotional benefit of cosmetic camouflage in the treatment of facial skin conditions: personal experience and review","volume":"5","author":"Levy","year":"2012","journal-title":"Clinical, Cosmetic and Investigational Dermatology"},{"issue":"36","key":"10.1002\/14651858.CD007478.pub2-BIB0241|cit241","first-page":"4100","article-title":"An overview of Chinese medicine in the treatment of systemic lupus erythematosus","volume":"21","author":"Li","year":"2012","journal-title":"Modern Journal of Integrated Traditional and Western Medicine"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0242|cit242","unstructured":"Livingston B Bonner A Pope J Differences in clinical manifestations between childhood onset lupus and adult onset lupus: a meta-analysis Reumatologia Clinica Suplementos Conference: 39th Congreso Mexico de Reumatologia edition Cancun, Quintana Roo, Mexico 2011 Conference Start: 2\/10\/2011 to 2\/15\/2011"},{"issue":"3","key":"10.1002\/14651858.CD007478.pub2-BIB0243|cit243","first-page":"293\u2013302","article-title":"Ginseng compounds: An update on their molecular mechanisms and medical applications","volume":"7","author":"Yao","year":"2009","journal-title":"Current Vascular Pharmacology"},{"issue":"3","key":"10.1002\/14651858.CD007478.pub2-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.autrev.2017.01.007","article-title":"Gender balance in patients with systemic lupus erythematosus","volume":"16","author":"Margery-Muir","year":"2017","journal-title":"Autoimmunity Reviews"},{"issue":"6","key":"10.1002\/14651858.CD007478.pub2-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","article-title":"Recommendations of screening for chloroquine and hydroxychloroquine retinopathy (2016 revision).American Academy of Ophthalmology Statement","volume":"123","author":"Marmor","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD007478.pub2-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1053\/sder.2001.23091","article-title":"Cutaneous lupus erythematosus","volume":"20","author":"McCauliffe","year":"2001","journal-title":"Seminars in Cutaneous Medicine and Surgery"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0247|cit247","volume-title":"Lupus erythematosus: clinical evaluation and treatment","author":"Merola","year":"2012"},{"issue":"1","key":"10.1002\/14651858.CD007478.pub2-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately to severely active systemic lupus erythematosus; the randomized, double blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/B978-0-323-47927-1.00039-6","volume-title":"Dubois' Lupus Erythematosus and Related Syndromes","author":"Miliaresis","year":"2019"},{"issue":"5","key":"10.1002\/14651858.CD007478.pub2-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/03009740701607042","article-title":"Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus: a systematic review","volume":"36","author":"Mok","year":"2007","journal-title":"Scandinavian Journal of Rheumatology"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0251|cit251","unstructured":"NHS National Institute of Health Research Horizon Scanning Centre University of Birmingham Tabalumab for systemic lupus erythematosus NIHR HSC ID: 5581"},{"issue":"2","key":"10.1002\/14651858.CD007478.pub2-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1016\/j.jisp.2017.02.001","article-title":"Cutaneous lupus: a brief review of mechanism of old and new therapeutic options","volume":"18","author":"Nutan","year":"2017","journal-title":"Journal of Investigative Dermatology Symposium Proceedings"},{"issue":"3","key":"10.1002\/14651858.CD007478.pub2-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1046\/j.1365-2133.2000.03356.x","article-title":"Measuring the activity of the disease in patients with cutaneous lupus erythematosus","volume":"142","author":"Parodi","year":"2000","journal-title":"British Journal of Dermatology"},{"issue":"8","key":"10.1002\/14651858.CD007478.pub2-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis and Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD007478.pub2-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/14740338.2017.1269168","article-title":"Hydroxychloroquine in systemic lupus erythematosus (SLE)","volume":"16","author":"Ponticelli","year":"2017","journal-title":"Expert Opinion on Drug Safety"},{"issue":"2","key":"10.1002\/14651858.CD007478.pub2-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/0961203316670731","article-title":"Biological therapies in the treatment of cutaneous lupus erythematosus","volume":"26","author":"Presto","year":"2017","journal-title":"Lupus"},{"issue":"11","key":"10.1002\/14651858.CD007478.pub2-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1093\/rheumatology\/kex260","article-title":"The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies","volume":"56","author":"Rees","year":"2017","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0258|cit258","unstructured":"Review Manager 5 (RevMan 5) Nordic Cochrane Centre, The Cochrane Collaboration 2014"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/B978-0-323-47927-1.00031-1","volume-title":"Dubois' Lupus Erythematosus and Related Syndromes","author":"Richardson","year":"2019"},{"issue":"12","key":"10.1002\/14651858.CD007478.pub2-BIB0260|cit260","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000467.pub2","article-title":"Calcium channel blockers for primary and secondary Raynaud's phenomenon","author":"Rirash","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD007478.pub2-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"438","DOI":"10.2174\/092986712803414312","article-title":"Novel and emerging drugs for systemic lupus erythematosus: mechanism of action and therapeutic activity","volume":"19","author":"Robak","year":"2012","journal-title":"Current Medicinal Chemistry"},{"issue":"3","key":"10.1002\/14651858.CD007478.pub2-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1191\/096120301666080831","article-title":"Methotrexate therapy in systemic lupus erythematosus","volume":"10","author":"Sato","year":"2001","journal-title":"Lupus"},{"issue":"3","key":"10.1002\/14651858.CD007478.pub2-BIB0263|cit263","first-page":"685","article-title":"Incidence studies of systemic lupus erythematosus in Southern Sweden. Increasing age, decreasing frequency of renal manifestations and good prognosis","volume":"27","author":"Stahl-Hallengren","year":"2000","journal-title":"Journal of Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD007478.pub2-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1191\/0961203303lu1034oa","article-title":"Clinical trial design in systemic lupus erythematosus: lessons learned and future directions","volume":"13","author":"Strand","year":"2004","journal-title":"Lupus"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0265|cit265","first-page":"1268","article-title":"A phase 1, randomized double-blind, placebo-controlled, multiple, intravenous, ascending dose study of sirukumab in patients with cutaneous or systemic lupus erythematosus","volume":"-","author":"Szepietowski","year":"2011","journal-title":"Arthritis and Rheumatology"},{"issue":"11","key":"10.1002\/14651858.CD007478.pub2-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/art.1780251101","article-title":"The 1982 Revised criteria for the classification of systemic lupus erythematosus","volume":"25","author":"Tan","year":"1982","journal-title":"Arthritis and Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD007478.pub2-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/096120339700600204","article-title":"Epidemiology and socioeconomic impact of skin disease in lupus erythematosus","volume":"6","author":"Tebbe","year":"1997","journal-title":"Lupus"},{"issue":"2","key":"10.1002\/14651858.CD007478.pub2-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1191\/096120398678919778","article-title":"A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group","volume":"7","author":"Tsakonas","year":"1998","journal-title":"Lupus"},{"issue":"4","key":"10.1002\/14651858.CD007478.pub2-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00228-007-0421-2","article-title":"Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence based evaluation","volume":"64","author":"Tzellos","year":"2008","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD007478.pub2-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/1529-0131(199901)42:1<46::AID-ANR6>3.0.CO;2-2","article-title":"Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992","volume":"42","author":"Uramoto","year":"1999","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0271|cit271","unstructured":"US Census Bureau: International Database (demographic data) www.census.gov\/popclock\/world"},{"issue":"2","key":"10.1002\/14651858.CD007478.pub2-BIB0272|cit272","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/bjd.12653","article-title":"The impact of skin damage due to cutaneous lupus on the quality of life","volume":"170","author":"Verma","year":"2014","journal-title":"British Journal of Dermatolology"},{"issue":"Suppl 16","key":"10.1002\/14651858.CD007478.pub2-BIB0273|cit273","first-page":"S17","article-title":"International survey on the management of patients with SLE. I. General data on the participating centers and the results of a questionnaire regarding mucocutaneous involvement","volume":"14","author":"Vitali","year":"1996","journal-title":"Clinical and Experimental Rheumatology"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0274|cit274","volume-title":"Dubois' Lupus Erythematosus","author":"Wallace","year":"2007"},{"issue":"6","key":"10.1002\/14651858.CD007478.pub2-BIB0275|cit275","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/11310780-000000000-00000","article-title":"Cutaneous lupus erythematosus: issues in diagnosis and treatment","volume":"10","author":"Walling","year":"2009","journal-title":"American Journal of Clinical Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD007478.pub2-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1159\/000246716","article-title":"Classification of lupus erythematosus based on cutaneous manifestations. Dermatological, systemic and laboratory findings in 191 patients","volume":"190","author":"Watanabe","year":"1995","journal-title":"Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD007478.pub2-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s12016-009-8192-4","article-title":"The unexplained female predominance of systemic lupus erythematosus: clues from genetic and cytokine studies","volume":"40","author":"Weckerle","year":"2011","journal-title":"Clinical Reviews in Allergy & Immunology"},{"issue":"5","key":"10.1002\/14651858.CD007478.pub2-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/j.1365-2133.2005.06784.x","article-title":"Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA","volume":"153","author":"Wenzel","year":"2005","journal-title":"British Journal of Dermatology"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD007478.pub2-BIB0279|cit279","first-page":"2591","article-title":"Association of smoking and cutaneous manifestations in systemic lupus erythematosus (sle): Post-hoc results from phase IIb studies of anifrolumab and sifalimumab","volume":"69","author":"Werth","year":"2017","journal-title":"Arthritis and Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD007478.pub2-BIB0280|cit280","first-page":"27","article-title":"Treatment of Cutaneous Lupus Erythematosus. review and assessment of treatment based on Oxford Centre for evidence-based medicine criteria","volume":"6","author":"Winkelmann","year":"2013","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0281|cit281","volume-title":"Comprehensive Dermatologic Drug Therapy","author":"Wolverton","year":"2001"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0282|cit282","volume-title":"Comprehensive Dermatologic Drug Therapy","author":"Wolverton","year":"2020"},{"issue":"1","key":"10.1002\/14651858.CD007478.pub2-BIB0283|cit283","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1550-8579(04)80006-8","article-title":"Gender differences in Systemic Lupus Erythematosus","volume":"1","author":"Yacob Wasef","year":"2004","journal-title":"Gender Medicine"},{"issue":"1","key":"10.1002\/14651858.CD007478.pub2-BIB0284|cit284","doi-asserted-by":"publisher","first-page":"14105","DOI":"10.1089\/act.2008.14105","article-title":"Lupus erythematosus and herbal medicine","volume":"14","author":"Yarnell","year":"2008","journal-title":"Alternative and Complementary Therapies"},{"key":"10.1002\/14651858.CD007478.pub2-BIB0285|cit285","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/B978-0-323-47927-1.00002-5","volume-title":"Dubois' Lupus Erythematosus","author":"Yazdany","year":"2019"},{"issue":"5","key":"10.1002\/14651858.CD007478.pub2-BIB0286|cit286","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1191\/096120301675962535","article-title":"Skin lesions- an indicator of disease activity in systemic lupus erythematosus","volume":"10","author":"Zecevic","year":"2001","journal-title":"Lupus"},{"issue":"4","key":"10.1002\/14651858.CD007478.pub2-BIB0287|cit287","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007478","article-title":"Interventions for cutaneous disease in systemic lupus erythematosus","author":"Hannon","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T09:38:29Z","timestamp":1704274709000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD007478.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Skin Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,3,9]]},"references-count":287,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007478.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,9]]}}}